{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:46:50Z","timestamp":1763621210668,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals SA","award":["UIDB\/04462\/2020","UIDP\/04462\/2020","LA\/P\/0087\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020","UIDP\/04462\/2020","LA\/P\/0087\/2020"]}]},{"name":"iNOVA4Health","award":["UIDB\/04462\/2020","UIDP\/04462\/2020","LA\/P\/0087\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020","UIDP\/04462\/2020","LA\/P\/0087\/2020"]}]},{"name":"the Associate Laboratory LS4FUTURE","award":["UIDB\/04462\/2020","UIDP\/04462\/2020","LA\/P\/0087\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020","UIDP\/04462\/2020","LA\/P\/0087\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Rotavirus A infection is a global leading cause of severe acute gastroenteritis associated with life-threatening diarrheal episodes in infants and young children. The disease burden is being reduced, namely due to a wider access to rotavirus vaccines. However, there is a demand to expand rotavirus vaccination programs, and to achieve this, it is critical to improve high-throughput in-process product quality control and vaccine manufacturing monitoring. Here, we present the development of an analytical method for the quantification of rotavirus particles contained in a licensed vaccine. The binding of rotavirus proteins to distinct glycoconjugate receptors and monoclonal antibodies was evaluated using biolayer interferometry analysis, applied on an Octet platform. The antibody strategy presented the best results with a linear response range within 2.5 \u00d7 107\u20131.0 \u00d7 108 particles\u00b7mL\u22121 and limits of detection and quantification of 2.5 \u00d7 106 and 7.5 \u00d7 106 particles\u00b7mL\u22121, respectively. Method suitability for the quantification of in-process samples was shown using samples from different manufacturing stages and their titers were comparable with the approved CCID(50) method. This cell-free method enables a fast and high-throughput analysis, compatible with time constraints during bioprocess development and it is suitable to be adapted to other viral particle-based drug products.<\/jats:p>","DOI":"10.3390\/vaccines10101585","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T04:07:07Z","timestamp":1663906027000},"page":"1585","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biolayer Interferometry Analysis for a Higher Throughput Quantification of In-Process Samples of a Rotavirus Vaccine"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5000-7217","authenticated-orcid":false,"given":"Sofia B.","family":"Carvalho","sequence":"first","affiliation":[{"name":"iBET, Instituto de Biologia Experimental e Tecnol\u00f3gica, Apartado 12, 2781-901 Oeiras, Portugal"},{"name":"Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica Ant\u00f3nio Xavier, Universidade Nova de Lisboa, Av. da Rep\u00fablica, 2780-157 Oeiras, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0289-061X","authenticated-orcid":false,"given":"Mafalda M.","family":"Dias","sequence":"additional","affiliation":[{"name":"iBET, Instituto de Biologia Experimental e Tecnol\u00f3gica, Apartado 12, 2781-901 Oeiras, Portugal"},{"name":"Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica Ant\u00f3nio Xavier, Universidade Nova de Lisboa, Av. da Rep\u00fablica, 2780-157 Oeiras, Portugal"}]},{"given":"Jean-Philippe","family":"Matheise","sequence":"additional","affiliation":[{"name":"GSK, Avenue Fleming 20, 1300 Wavre, Belgium"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8303-4921","authenticated-orcid":false,"given":"Isabelle","family":"Knott","sequence":"additional","affiliation":[{"name":"GSK, Rue de l\u2019Institut 89, 1330 Rixensart, Belgium"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-6785","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Gomes-Alves","sequence":"additional","affiliation":[{"name":"iBET, Instituto de Biologia Experimental e Tecnol\u00f3gica, Apartado 12, 2781-901 Oeiras, Portugal"},{"name":"Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica Ant\u00f3nio Xavier, Universidade Nova de Lisboa, Av. da Rep\u00fablica, 2780-157 Oeiras, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1445-3556","authenticated-orcid":false,"given":"Paula M.","family":"Alves","sequence":"additional","affiliation":[{"name":"iBET, Instituto de Biologia Experimental e Tecnol\u00f3gica, Apartado 12, 2781-901 Oeiras, Portugal"},{"name":"Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica Ant\u00f3nio Xavier, Universidade Nova de Lisboa, Av. da Rep\u00fablica, 2780-157 Oeiras, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/jamapediatrics.2018.1960","article-title":"Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years","volume":"172","author":"Troeger","year":"2018","journal-title":"JAMA Pediatr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/jpids\/piab114","article-title":"Global Estimates of Rotavirus Hospitalizations Among Children Below 5 Years in 2019 and Current and Projected Impacts of Rotavirus Vaccination","volume":"11","author":"Hallowell","year":"2022","journal-title":"J. Pediatric. Infect Dis. Soc."},{"key":"ref_3","unstructured":"(2022, January 20). World Health Organization Vaccine in National Immunization Programme Update. Available online: Www.Who.Int\/Immunization\/Monitoring_surveillance\/VaccineIntroStatus.Pptx?Ua=1."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/QCO.0000000000000572","article-title":"Current and New Rotavirus Vaccines","volume":"32","author":"Burke","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e885","DOI":"10.1016\/S2214-109X(21)00265-5","article-title":"Rotavirus Vaccine Implementation: Evidence to Fill the Gap?","volume":"9","author":"Buttery","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/cid\/ciab442","article-title":"Rotavirus Vaccination Likely to Be Cost Saving to Society in the United States","volume":"73","author":"Newall","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S792","DOI":"10.1093\/infdis\/jiab399","article-title":"Global Experience With Rotavirus Vaccines","volume":"224","author":"Burke","year":"2021","journal-title":"J. Infect Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.vaccine.2015.03.016","article-title":"Effectiveness and Impact of Rotavirus Vaccines in Europe, 2006\u20132014","volume":"33","author":"Karafillakis","year":"2015","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.1016\/j.vaccine.2017.03.076","article-title":"The Rotavirus Vaccine Development Pipeline","volume":"37","author":"Kirkwood","year":"2019","journal-title":"Vaccine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.cmi.2015.01.027","article-title":"Rotavirus Vaccines: A Story of Success","volume":"21","author":"Kollaritsch","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/cid\/ciq101","article-title":"Case-Control Evaluation of the Effectiveness of the G1P [8] Human Rotavirus Vaccine during an Outbreak of Rotavirus G2P [4] Infection in Central Australia","volume":"52","author":"Snelling","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1093\/cid\/civ1016","article-title":"Effectiveness of Pentavalent Rotavirus Vaccine Under Conditions of Routine Use in Rwanda","volume":"62","author":"Tate","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1080\/21645515.2020.1801071","article-title":"The Performance of Licensed Rotavirus Vaccines and the Development of a New Generation of Rotavirus Vaccines: A Review","volume":"17","author":"Wang","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41541-021-00317-4","article-title":"Considerations for Bioanalytical Characterization and Batch Release of COVID-19 Vaccines","volume":"6","author":"Sanyal","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/d41573-020-00151-8","article-title":"Evolution of the COVID-19 Vaccine Development Landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 Vaccine Development Landscape","volume":"19","author":"Andreadakis","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jviromet.2005.08.013","article-title":"Development and Application of a Quantitative RT-PCR Potency Assay for a Pentavalent Rotavirus Vaccine (RotaTeq\u00ae)","volume":"131","author":"Ranheim","year":"2006","journal-title":"J. Virol. Methods"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1700031","DOI":"10.1002\/biot.201700031","article-title":"Universal Label-Free in-Process Quantification of Influenza Virus-like Particles","volume":"12","author":"Carvalho","year":"2017","journal-title":"Biotechnol. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.vaccine.2019.01.083","article-title":"SPRi-Based Hemagglutinin Quantitative Assay for Influenza Vaccine Production Monitoring","volume":"37","author":"Durous","year":"2019","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.vaccine.2009.10.070","article-title":"A Novel Assay for Influenza Virus Quantification Using Surface Plasmon Resonance","volume":"28","author":"Nilsson","year":"2010","journal-title":"Vaccine"},{"key":"ref_21","unstructured":"European Medicines Agency (1995). ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology (CPMP\/ICH\/381\/95)."},{"key":"ref_22","unstructured":"Food and Drug Administration (1996). ICH Guidance for Industry, Q2B Validation of Analytical Procedures: Methodology (FDA-1996-D-0169)."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical Methods for Assessing Agreement between Two Methods of Clinical Measurement","volume":"327","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrmicro3346","article-title":"The Sweet Spot: Defining Virus\u2013Sialic Acid Interactions","volume":"12","author":"Reiss","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.virusres.2014.06.016","article-title":"Rotaviruses","volume":"190","author":"Desselberger","year":"2014","journal-title":"Virus Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1750-2659.2012.00375.x","article-title":"Development of an Enzyme-Linked Immunoassay for the Quantitation of Influenza Haemagglutinin: An Alternative Method to Single Radial Immunodiffusion","volume":"7","author":"Bodle","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.vaccine.2014.02.049","article-title":"Novel Antibody-Independent Receptor-Binding SPR-Based Assay for Rapid Measurement of Influenza Vaccine Potency","volume":"32","author":"Khurana","year":"2014","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature13443","article-title":"Receptor Binding by H10 Influenza Viruses","volume":"511","author":"Vachieri","year":"2014","journal-title":"Nature"},{"key":"ref_29","unstructured":"Pall Life Sciences Biomolecular Binding Kinetics Assays on the Octet Platform (2022, July 31). Application Note 14. Available online: http:\/\/separations.co.za\/wp-content\/uploads\/2017\/05\/OCTET.pdf."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/10\/1585\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:36:32Z","timestamp":1760142992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/10\/1585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["vaccines10101585"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10101585","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2022,9,21]]}}}